Awaiting committee decision
Next event: Indicative plenary sitting date, 1st reading/single reading 2014/04/02
Role | Committee | Rapporteur | Shadows |
---|---|---|---|
Lead | CONT | SARVAMAA Petri (EPP) | KADENBACH Karin (S&D), GERBRANDY Gerben-Jan (ALDE), STAES Bart (Verts/ALE), ANDREASEN Marta (ECR), DE JONG Cornelis (GUE/NGL), VANHECKE Frank (EFD), EHRENHAUSER Martin (NI) |
Opinion | ENVI | HAUG Jutta (S&D) |
Activites
-
2014/04/02
Indicative plenary sitting date, 1st reading/single reading
-
2013/10/22
Committee referral announced in Parliament, 1st reading/single reading
-
2013/07/26
Non-legislative basic document published
-
COM(2013)0570
summary
PURPOSE: presentation by the Commission of the consolidated annual accounts of the European Union for the financial year 2012, as part of the 2012 discharge procedure. Analysis of the accounts of the European Medicines Agency (EMEA). CONTENT: this Commission document sets out the consolidated annual accounts of the European Union for the financial year 2012 as prepared on the basis of the information presented by the institutions, organisations and bodies of the EU, in accordance with Article 129 (2) of the Financial Regulation applicable to the EU's General Budget, including the European Medicines Agency (EMEA). In 2012, the tasks and budget of this agency were as follows: · description of the Agency's tasks: the European Medicines Agency, which is located in London, was created by Council Regulation (EEC) No 2309/93, which was replaced by Regulation (EC) No 726/2004 of the European Parliament and of the Council and its role is the coordination of the scientific resources made available by the national authorities in order to ensure the evaluation and supervision of medicinal products for human or veterinary use on the basis of a centralised procedure; · the Agency's budget for the 2012 financial year: the Agency’s budget for 2012, as presented in the Commission document on the consolidated annual accounts of the European Union, gives the following figures: § Commitment appropriations: - committed : EUR 226 million; - paid : EUR 222 million; - carried over : 0. § Payment appropriations: - committed : EUR 262 million; - paid : EUR 215 million; - carried over : EUR 41 million. See also the final accounts of the EMA.
- DG {'url': 'http://ec.europa.eu/dgs/budget/', 'title': 'Budget'}, ŠEMETA Algirdas
-
COM(2013)0570
summary
Documents
- Non-legislative basic document published: COM(2013)0570
Amendments | Dossier |
29 |
2013/2215(DEC)
2013/12/18
ENVI
9 amendments...
Amendment 1 #
Draft opinion Paragraph 1 1. Notes that in 2012 the European Medicines Agency had resources available of EUR 222.489 000 of which EUR 28.966 000 had been EU budget contributions; likes to stress that this amount represents 0.021% of the overall EU budget; is satisfied that 575 of 590 available posts had been occupied and notes that 160 contract agents and seconded national experts were employed by the end of 2012 which are 17 less than in 2011;
Amendment 2 #
Draft opinion Paragraph 3 3.
Amendment 3 #
Draft opinion Paragraph 3 3.
Amendment 4 #
Draft opinion Paragraph 3 3. Recognises the three comments made by the Court of Auditors which focus
Amendment 5 #
Draft opinion Paragraph 4 4. Reiterates the important role of the Agency in protecting and promoting public and animal health by assessing and supervising medicines for human or veterinary use; welcomes the policy on the handling of conflict of interests, last updated and endorsed by the Management Board in March 2012; welcomes the adoption of the Agency draft policy on publication and access to clinical-trial data.
Amendment 6 #
Draft opinion Paragraph 4 a (new) 4a. Believes that the discharge decision should be based upon OECD guidelines to ensure high quality internationally recognised accounting, audit and financial disclosure standards; invites the European institutions to incorporate and commit to introducing OECD guidelines within a common framework for all European institutions and bodies;
Amendment 7 #
Draft opinion Paragraph 4 a (new) 4a. Believes that the discharge decision should be based upon OECD guidelines to ensure high quality internationally recognised accounting, audit and financial disclosure standards; invites the European institutions to incorporate and commit to introducing OECD guidelines within a common framework for all European institutions and bodies;
Amendment 8 #
Draft opinion Paragraph 5 5. Recommends
Amendment 9 #
Draft opinion Paragraph 5 5. Recommends
source: PE-526.144
2014/02/25
CONT
20 amendments...
Amendment 1 #
Proposal for a decision 1 Paragraph 1 1. Grants the Executive Director of the European Medicines Agency discharge in respect of the implementation of the Agency's budget for the financial year
Amendment 10 #
Motion for a resolution Recital A a (new) Aa. whereas according to its financial statements, the overall contribution of the Union to the Agency's budget for 2012 amounted to EUR 31 341 107.18, representing a decrease of 6, 50 % compared to 2011,
Amendment 11 #
Motion for a resolution Paragraph 4 4. Regrets that the Agency has not yet validated its accounting system in the area of intangible fixed assets, which, given the considerable investment in the development of information and communications technology (ICT), is a crucial part of the whole accounting system; calls on the Agency to inform the discharge authority on progress in this regard
Amendment 12 #
Motion for a resolution Paragraph 8 8. Notes with concern that in 2012, the Agency issued multiple framework
Amendment 13 #
Motion for a resolution Subheading 6 a (new) Prevention and management of conflicts of interests and transparency
Amendment 15 #
Motion for a resolution Paragraph 10 a (new) 10a. Welcomes the fact that for the second year in a row, the Agency held a public workshop on conflicts of interests, aimed at defining the right balance between ensuring the impartiality and independence of experts involved in the Agency's work while securing the best possible scientific expertise;
Amendment 16 #
Motion for a resolution Paragraph 10 a (new) 10a. Looks forward to the revised version of the Agency's conflicts of interests policy; emphasises that the Agency should continue its work to further strengthen its conflicts of interest policy;
Amendment 17 #
Motion for a resolution Paragraph 10 b (new) 10b. Acknowledges that the Agency revised its policy on the handling of conflicts of interests by the Scientific Committees' members and experts which is expected for endorsement by the Management Board in March 2014; calls on the Agency to present its revised policy to the discharge authority once adopted;
Amendment 18 #
Motion for a resolution Paragraph 10 b (new) 10b. Notes that the Agency works together closely with a variety of patient, healthcare and consumer organisations in order to take their opinions into account; calls on the Agency to request the public disclosure of funding information of any patient, consumer and healthcare organisation and to carry out a conflicts of interests check before the Agency involves them in its work;
Amendment 19 #
Performance
Amendment 2 #
Proposal for a decision 1 Paragraph 1 1. Grants the Executive Director of the European Medicines Agency discharge in respect of the implementation of the Agency's budget for the financial year
Amendment 20 #
Motion for a resolution Paragraph 11 a (new) 11a. Requests that the Agency communicate the results and impact its work has on European citizens in an accessible way, mainly through its website;
Amendment 3 #
Proposal for a decision 1 Paragraph 1 1.
Amendment 4 #
Proposal for a decision 1 Paragraph 1 1.
Amendment 5 #
Proposal for a decision 2 Paragraph 1 1.
Amendment 6 #
Proposal for a decision 2 Paragraph 1 1. Approves the closure of the accounts of the European Medicines Agency for the financial year
Amendment 7 #
Proposal for a decision 2 Paragraph 1 1. Approves the closure of the accounts of the European Medicines Agency for the financial year
Amendment 8 #
Motion for a resolution Citation 10 a (new) – having regard to the previous discharge reports of the Parliament;
Amendment 9 #
Motion for a resolution Recital A A. whereas, according to its financial statements, the final budget of the European Medicines Agency (
source: PE-521.807
|
History
(these mark the time of scraping, not the official date of the change)
activities/2/type |
Old
Indicative plenary sitting date, 1st reading/single readingNew
Debate in plenary scheduled |
activities/3 |
|
activities/0/docs/0/celexid |
Old
CELEX:52013PC0570:ENNew
CELEX:52013DC0570:EN |
activities/0/docs/0/celexid |
Old
CELEX:52013DC0570:ENNew
CELEX:52013PC0570:EN |
activities/0/type |
Old
Non-legislative basic documentNew
Non-legislative basic document published |
activities/1 |
|
procedure/dossier_of_the_committee |
CONT/7/13880
|
procedure/stage_reached |
Old
Preparatory phase in ParliamentNew
Awaiting committee decision |
activities/0/docs/0/celexid |
Old
CELEX:52013PC0570:ENNew
CELEX:52013DC0570:EN |
activities/0/docs/0/celexid |
Old
CELEX:52013DC0570:ENNew
CELEX:52013PC0570:EN |
activities/0/docs/0/celexid |
CELEX:52013DC0570:EN
|
activities/0/docs/0/celexid |
CELEX:52013DC0570:EN
|
committees/0/shadows/3 |
|
activities/0/docs/0/text |
|
activities/0/docs/0/url |
http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2013&nu_doc=570
|
activities |
|
committees |
|
links |
|
other |
|
procedure |
|